Last reviewed · How we verify
fenoldopam infusion
Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow.
Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow. Used for Acute hypertension in hospitalized patients, Hypertensive emergency.
At a glance
| Generic name | fenoldopam infusion |
|---|---|
| Also known as | fenoldopam administration (0.08 mcg/Kg/min) |
| Sponsor | University of Roma La Sapienza |
| Drug class | Dopamine-1 receptor agonist |
| Target | Dopamine-1 (DA1) receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fenoldopam selectively binds to dopamine-1 receptors on vascular smooth muscle and renal vasculature, leading to peripheral and renal vasodilation. This results in decreased systemic vascular resistance, lowered blood pressure, and increased renal perfusion, making it useful for acute hypertensive episodes and renal protection in critical care settings.
Approved indications
- Acute hypertension in hospitalized patients
- Hypertensive emergency
Common side effects
- Tachycardia
- Headache
- Flushing
- Nausea
- Hypotension
Key clinical trials
- Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants (PHASE2, PHASE3)
- The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery (NA)
- Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery (PHASE3)
- Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury (PHASE4)
- Effect of Gene Variants on Dopamine Receptor Natriuretic Responses (PHASE1)
- Fenoldopam for Prevention of Acute Kidney Injury (PHASE4)
- Fenoldopam in Pediatric Cardiac Surgery (PHASE3)
- Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fenoldopam infusion CI brief — competitive landscape report
- fenoldopam infusion updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI